Studies tumor samples from people with rare cervical neuroendocrine cancer
Looks at stored tumor samples and records from people with rare cervical neuroendocrine cancer.
Plain-language title generated from the registry record
Registry title: Multi-omics Study of Cervical Neuroendocrine Carcinoma
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07879339, who can take part
Where in China
- Peking Union Medical College HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- NCT07879339
- Record updated
- 16 October 2026
- Original description
This is a retrospective study using archived tumor tissue and medical records from patients with cervical neuroendocrine carcinoma treated at Peking Union Medical College Hospital since January 1, 2015. Cervical neuroendocrine carcinoma is a rare and highly aggressive cervical cancer with no standard treatment. The study will analyze the tumor's genes, RNA, proteins, and immune environment to better understand its molecular features, identify molecular subtypes, find markers related to survival and immunotherapy, and build a prognostic prediction model. No new patients will be enrolled, and no additional tests or treatments will be given. About 80-120 patients are expected to be included. Results may help improve future diagnosis and personalized treatment for this rare cancer.Read full original descriptionShow less
A Real-World Retrospective Multi-Omics Study of Cervical Neuroendocrine Carcinoma
This is a retrospective study using archived tumor tissue and medical records from patients with cervical neuroendocrine carcinoma treated at Peking Union Medical College Hospital since January 1, 2015. Cervical neuroendocrine carcinoma is a rare and highly aggressive cervical cancer with no standard treatment. The study will analyze the tumor's genes, RNA, proteins, and immune environment to better understand its molecular features, identify molecular subtypes, find markers related to survival and immunotherapy, and build a prognostic prediction model. No new patients will be enrolled, and no additional tests or treatments will be given. About 80-120 patients are expected to be included. Results may help improve future diagnosis and personalized treatment for this rare cancer.
Inclusion: 1: Inclusion criteria Age ≥ 18 years; 2: Histopathologically confirmed neuroendocrine carcinoma of the cervix (including small cell type, large cell type, and mixed type), reviewed and confirmed by at least two pathologists; 3: Sufficient quality and quantity of archived tumor tissue specimens available for multi-omics testing (formalin-fixed paraffin-embedded tissue sections ≥ 10 slides or fresh frozen tissue ≥ 50 mg); 4: Complete clinical medical records and follow-up data (including at least diagnostic information, treatment regimen, and survival follow-up).
Exclusion: 1: Failure to meet all of the above inclusion criteria; 2: Archived tumor tissue specimens of inadequate quality for multi-omics testing; 3: Severely missing key clinical data that preclude the extraction of valid information; 4: Concomitant other malignancies (excluding non-melanoma skin cancer).